Leopoldo Baiza-Durán

Dr. Leopoldo Baiza-Durán

Sociedad Mexicana para la Divulgación de la Ciencia y la Técnica

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
Homero Contreras-SalinasHomero Contreras-Salinas
Homero Contreras-Salinas
LBLeopoldo Baiza-Durán
Leopoldo Baiza-Durán
MBManuel Alejandro Bautista-Castro
Manuel Alejandro Bautista-Castro
DADiego Rodrigo Alonso-Rodríguez
Diego Rodrigo Alonso-Rodríguez
LRLourdes Yolotzin Rodríguez-Herrera
Lourdes Yolotzin Rodríguez-Herrera
(1) Aims of the study: calculating the underreporting ratio for two different medications, a fixed combination of 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide (antiglaucoma) and a fixed combination of sodium hyaluronate 0.1% + chondroitin sulfate 0.18% (artificial tears) for characterizing the features influencing the reporting of adverse drug reactions (ADRs) in spontaneous reporting. (2) Methods: The underreporting ratio was calculated by comparing the adverse drug reactions reported in the spontaneous reporting database for every 10,000 defined daily doses marketed and the adverse drug reactions from an active surveillance study for every 10,000 defined daily doses used for different drugs (antiglaucoma and artificial tears). The factors related to the report in spontaneous reporting through statistical tests were also determined. (3) Results: The underreporting ratio of spontaneous reporting was 0.006029% for antiglaucoma and 0.003552% for artificial tears. Additionally, statistically significant differences were found for severity, unexpected adverse drug reactions, and incidence of adverse drug reactions in females when compared with spontaneous reporting and active surveillance. (4) Conclusions: The underreporting ratio of ADRs related to ophthalmic medications indicates worry since the cornerstone of pharmacovigilance focuses on spontaneous reporting. Additionally, since underreporting seems to b selective, the role of certain aspects, such as gender, seriousness, severity, and unexpected ADRs, must be considered in future research.

10 January 2021 in Pharmacy
Verified
Journal Article
Open access
PDF file
Homero Contreras-SalinasHomero Contreras-Salinas
Homero Contreras-Salinas
LBLeopoldo Baiza-Durán
Leopoldo Baiza-Durán
MBMariana Barajas-Hernández
Mariana Barajas-Hernández
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
LRLourdes Yolotzin Rodríguez-Herrera
Lourdes Yolotzin Rodríguez-Herrera
(1) Background: drugs provide a significant benefit for patients who require medical treatment; however, their use implies an intrinsic potential danger, with the possibility of causing unwanted effects. These effects are known as adverse drug reactions (ADRs). Post-marketing drug safety surveillance detects unknown risks that have not been identified in clinical trials, and it is necessary to monitor marketed medications under real-life practice. Due to the scarce information about fixed combination of ciprofloxacin 0.3%/dexamethasone 0.1% (SDO), we performed a drug safety surveillance study. (2) Methods: A prospective non-controlled drug safety surveillance study was conducted in Peruvian population. A total of 236 patients prescribed SDO were included derived from 12 sites. Patients’ standardized information was collected through two phone calls, including demographics, medical history, prescribing patterns of SDO, concomitant medication, and ADRs in detail. The ADRs were classified by causality and severity, followed by outcome measures to identify new risk. (3) Results: 236 patients prescribed with SDO participated in the study and 220 were included. A total of 82 ADRs/220 patients were reported after the use of SDO, presenting a ratio 0.37 ADR/patient. The most frequent ADR with SDO administration was eye irritation (30%). All ADRs were classified as non-serious, and 97.5% (n = 80) were classified as mild while 2.5% as moderate (n = 2). No cases under the severe category were identified. (4) Conclusion: No new risks were found in the population where this study was conducted.

11 October 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
Homero Contreras-SalinasHomero Contreras-Salinas
Homero Contreras-Salinas
LBLeopoldo Baiza-Durán
Leopoldo Baiza-Durán
MBManuel Alejandro Bautista-Castro
Manuel Alejandro Bautista-Castro
DADiego Rodrigo Alonso-Rodríguez
Diego Rodrigo Alonso-Rodríguez
LRLourdes Yolotzin Rodríguez-Herrera
Lourdes Yolotzin Rodríguez-Herrera
(1)Aims of the study: calculating the underreporting ratio for two different medications, a fixed combination of 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide (antiglaucoma) and a fixed combination of sodium hyaluronate 0.1% + chondroitin sulfate 0.18% (artificial tear) and characterizing the features influencing the reporting of adverse drug reactions (ADRs) in spontaneous reporting; (2) Methods: the underreporting ratio was calculated by comparing the adverse drug reactions reported in the spontaneous reporting database for every 10,000 defined daily doses marketed and the adverse drug reactions from an active surveillance study for every 10,000 defined daily doses used for different drugs (antiglaucoma and artificial tear). The factors related to the report in spontaneous reporting through statistical tests were also determined; (3) Results: The underreporting ratio of spontaneous reporting was 0.006029% for antiglaucoma and 0.003552% for artificial tear; additionally, statistically significant differences were found for severity, unexpected adverse drug reactions, and incidence of adverse drug reactions in females; (4) Conclusions: The underreporting ratio of ADRs related to ophthalmic medications indicates worry since the cornerstone of pharmacovigilance focuses on spontaneous reporting. Besides, since underreporting seems to be selective, the role of certain aspects like gender, seriousness, severity, and unexpected ADRs, must be considered in future research.

25 November 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
Homero Contreras-SalinasHomero Contreras-Salinas
Homero Contreras-Salinas
LBLeopoldo Baiza-Durán
Leopoldo Baiza-Durán
MBMariana Barajas-Hernández
Mariana Barajas-Hernández
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
LRLourdes Yolotzin Rodríguez-Herrera
Lourdes Yolotzin Rodríguez-Herrera
(1) Background: drugs provide a significant benefit; however, their use implies an intrinsic potential danger, with the possibility to cause unwanted effects. These effects are known as adverse drug reactions (ADRs). Post-marketing drug safety surveillance detects unknown risks that have not been identified in clinical trials and it is necessary to monitor marketed medications under real-life practice. Due to the scarce information about fixed combination of ciprofloxacin 0.3% / dexamethasone 0.1% (SDO), we performed a drug safety surveillance study. (2) Methods: A prospective non-controlled drug safety surveillance study was conducted in Peruvian population. A total of 236 patients prescribed SDO were included derivates from 12 sites. Patients' standardized information was collected through two phone calls, including demographics, medical history, prescribing patterns of SDO, concomitant medication, and ADRs in detail. The ADRs were classified by causality and severity, followed by outcome measures to identify new risk. (3) Results: 236 patients prescribed with SDO participated in the study and 220 were included. A total of 82 ADRs/220 patients were reported after the use of SDO, presenting a ratio 0.37 ADR/patient. The most frequent ADR with SDO administration was eye irritation (30%). The totality of the ADR was classified as non-serious, and the 97.5% (n=80) was classified as mild and 2.5% as moderate (n=2). No cases under the severe category were identified. (4) Conclusion: No new risks were found in the population where this study was conducted.